![Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination – touchENDOCRINOLOGY Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination – touchENDOCRINOLOGY](https://www.touchendocrinology.com/wp-content/uploads/sites/5/2021/04/Fig-5.jpg)
Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination – touchENDOCRINOLOGY
![Our response to the withdrawal of dapagliflozin (Forxiga) for type 1 diabetes - JDRF, the type 1 diabetes charity Our response to the withdrawal of dapagliflozin (Forxiga) for type 1 diabetes - JDRF, the type 1 diabetes charity](https://jdrf.org.uk/wp-content/uploads/2022/02/woman-taking-tablet-dapagliflozin-type-1-diabetes.jpg)
Our response to the withdrawal of dapagliflozin (Forxiga) for type 1 diabetes - JDRF, the type 1 diabetes charity
![Medicina | Free Full-Text | Benefit or Risk in Patient with Type 1 Diabetes Based on Appropriated Dosage of Dapagliflozin: A Case Report Medicina | Free Full-Text | Benefit or Risk in Patient with Type 1 Diabetes Based on Appropriated Dosage of Dapagliflozin: A Case Report](https://www.mdpi.com/medicina/medicina-59-00827/article_deploy/html/images/medicina-59-00827-g001.png)
Medicina | Free Full-Text | Benefit or Risk in Patient with Type 1 Diabetes Based on Appropriated Dosage of Dapagliflozin: A Case Report
![Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial - The Lancet Diabetes & Endocrinology Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial - The Lancet Diabetes & Endocrinology](https://www.thelancet.com/cms/attachment/0c43ee8e-6bce-4fcb-bbc6-51c44c347ed9/gr1.gif)
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial - The Lancet Diabetes & Endocrinology
Wichtige Sicherheitsinformationen zum Risiko einer Diabetischen Ketoazidose (DKA) unter Forxiga 5 mg (Dapagliflozin) zur Anwen
![Zulassungsänderung - Keine Anwendung von Dapagliflozin bei Typ-1-Diabetes mellitus • diabetologie-online Zulassungsänderung - Keine Anwendung von Dapagliflozin bei Typ-1-Diabetes mellitus • diabetologie-online](http://www.diabetologie-online.de/_storage/asset/2354473/storage/kirchheim:article-2_04-1/file/355233088/26724553.jpg)